Lisofylline
Title: Lisofylline
CAS Registry Number: 100324-81-0
CAS Name: 3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione
Additional Names: 1-[(R)-5-hydroxyhexyl]theobromine; 1-(5R-hydroxyhexyl)-3,7-dimethylxanthine
Manufacturers' Codes: CT-1501R
Trademarks: ProTec (Cell Therapeutics)
Molecular Formula: C13H20N4O3
Molecular Weight: 280.32
Percent Composition: C 55.70%, H 7.19%, N 19.99%, O 17.12%
Literature References: Methylxanthine that inhibits production of phosphatidic acid during the inflammatory response. Identification as metabolite of pentoxifylline: H.-J. Hinze et al., Arzneim.-Forsch. 22, 1144 (1972). Enantioselective process: W. Aretz et al., DE 3942872; eidem, US 5310666 (1991, 1994 both to Hoechst). Asymmetric synthesis: J. P. Klein et al., WO 9531450 (1995 to Cell Therapeutics). Study of mechanism of action in septic shock: G. C. Rice et al., Proc. Natl. Acad. Sci. USA 91, 3857 (1994). Enhancement of hematopoietic recovery following 5-fluorouracil treatment in mice: E. Clarke et al., Cancer Res. 56, 105 (1996).
Properties: mp 110°. [a]D20 -5.6° (c = 6.7 in ethanol).
Melting point: mp 110°
Optical Rotation: [a]D20 -5.6° (c = 6.7 in ethanol)
Therap-Cat: Immunomodulator.
Keywords: Immunomodulator.

Others monographs:
PhillyrinEtonitazeneSulphan Blue5-Methylcytosine
NeoergosterolAcetazolamideNebularinePropipocaine
Sodium BenzoateAmbusideDimethylthiambutene2-Thiolhistidine
PipotiazineHanatoxinsPhosphineMOPS
©2016 DrugLead US FDA&EMEA